INTRODUCTION
T he Olsen and Gøtzsche meta-analysis questioned the efficacy of breast cancer screening. 1 Although the criticisms of the screening trials have largely been answered, 2 a topic of continuing interest is the overdiagnosis and over-treatment of malignant neoplasms that have no clinical relevance. 3, 4 Other potentially harmful outcomes of screening have not been studied: no large study, to date, has compared the incidence rate of surgical treatment of benign neoplasms in and out of screening programmes.
Efficacy is measured by comparing the screened with the not-screened groups. Women in the not-screened groups are also subject to clinical and preventive mammograms. Therefore, any comparison between the two depends on the quality of both preventive diagnostic procedures of the screening programmes and clinical diagnostic procedures out of screening programmes. 5, 6 The results of organized Screening Programmes (SPs) are easy to describe, given the possibility of calculating detection rate and positive predictive value, and there is a vast literature on how to report them, 7 but little is known, at least in Italy, about the results of the diagnostic-therapeutic procedures performed out of screening programmes. 8, 9 Now, 25 years after the first trials, [10] [11] [12] we know that about 67% of the target population in our region regularly undergoes preventive mammograms, 13 80% of whom were not contacted by the SPs.
In our region, SPs started at different times in each Local Health Unit (LHU), none of which contacted the entire target population within the expected two years of the screening round. This situation allowed us to study the incidence of breast surgery for neoplasm in two populations in the same area and during the same period, without any self-selection: the contacted women and the not-yetcontacted women. This is the first paper where a comparison of the incidence of surgery for benign neoplasm in women contacted by SPs and woman not contacted by SPs has been done. We present the incidence of breast surgery for benign and malignant neoplasm in the contacted population and in the not-yet-contacted population, and, among those contacted, we compare the screened women (compliant) with the non-compliant women. round of screening, planned for 1 July 1999 to 30 June 2001. Only six LHUs (target population 356,896) out of 12 actually started contacting women during the study period.
The data sources
Since 1995, the Hospital Information System (HIS) of the Lazio region had routinely collected discharge abstract data from all Lazio hospitals, including patient demographic data, admission and discharge dates, discharge status, up to six discharge diagnoses (International Classification of Disease [ICD]-9-CM), and up to six procedures (ICD-9-CM).
Since 1999, the inter-regional mobility data-set had collected all the hospitalizations of residents of Lazio that occurred out of the region.
Since 1999, the Mammography Screening Information System (MSIS) had routinely collected individual data on the screening activity of SPs in Latium region into a centralized database, including patient demographic data, contact date, exclusion and reasons for exclusion, dates and results of primary screening tests and second level tests, and final recommendations.
Data selection
We identified within the HIS all diagnostic or therapeutic breast surgical treatments (ICD-9-CM codes 85) for neoplasm between 1 July 1999 and 30 June 2003 in women aged 50-69 years during the study period (1 July 1999-30 June 2001). Cases were classified as benign (ICD-9-CM codes 217.0-217.9; 238.3; 239.3) or malignant (ICD-9-CM codes 174.0-174.9; 233.0). We performed separate analyses, including and not including diagnostic procedures (both percutaneous and surgical ICD-9-CM codes 85.1) for benign neoplasms (see Table 1 for the selection of cases).
We excluded all prevalent cases with a diagnosis of breast cancer by checking for previous hospitalization between 1995 and 30 June 1999 or for the ICD-9-CM code V10.3 (history of breast cancer). Another 19 cases were classified as prevalent and excluded according to the medical history present in the MSIS.
Data analysis
We calculated person-time at risk (that is, the number of people multiplied by the number of years of observation) according to three categories: no active SP; not yet contacted and contacted:
No active SP: all the women of target age resident in the LHUs that did not conduct screening, for the entire study period (1 July 1999 -30 June 2001 .
Not-yet-contacted: person time after 1 July 1999 but before being contacted for screening, for residents of LHUs with active SP. This also includes the women never contacted and women who presented themselves spontaneously for screening.
Contacted: includes person time after the first contact and is classified into: J Non-compliant: contacted women who did not participate. J Compliant: two groups of women who were screened:
Positive: all women whose last referral indicated surgery or additional tests.
Negative: all women referred to the next screening round (i.e. intervals X1 year), and the women for whom test results were missing.
We linked incident cases with the MSIS by first name, family name and birth date; after linkage, we checked for other prevalent cases on the basis of the medical history present in MSIS records.
According to the results of the linkage, we classified the breast neoplasm surgery cases as follows:
Screen detected: all compliant, positive women surgically treated in the two years following the test.
Interval cases: all compliant, negative women surgically treated in the two years following the test.
Clinical cases in non-compliant: all non-compliant
women surgically treated in the two years following the test.
Clinical cases: all women aged 50-69 years not contacted but surgically treated during the study period.
Incidence in the not contacted population were computed separately for LHUs with and without active SP.
Incidence and the incidence rate ratios were adjusted for age and breast cancer standardized mortality ratio (SMR) of the residence municipality based on mortality registry data 14 and were calculated using a Poisson model. 15 We calculated the positive predictive value of the diagnostic procedures, considering all treated malignant neoplasms as true positives and all benign neoplasms as false positives.
Table1 ICD-9-CM codes for diagnosis and therapeutic procedures used in the case selection Therapeutic breast surgical treatments: ICD-9-CM codes and description
Diagnosis
Only diagnostic 85. We defined the 'proportional interval cancer incidence' for the first and second year after screening as the ratio between the observed number of interval cancers and the expected number of cases without screening based on the incidence rate in the not-yet-contacted women. Table 2 compares the characteristics of the contacted and the not-contacted population by age and breast cancer mortality rate of the residence area. The target population numbered 681,000: 324,000 were residents in the six LHUs without active screening programmes and could not be contacted; in the other six LHUs 116,403 people were contacted and 46,937 complied. In all, 4303 women were excluded because they presented themselves spontaneously (8.5% of the tests).
RESULTS
We identified 1861 women who underwent surgery for benign neoplasm; we decided to exclude 295 of them who underwent diagnostic procedures (ICD-9-CM code 85.1). We also identified 3252 women who underwent surgical treatment for malignant breast neoplasm, 95 of which had an in situ carcinoma (ductal or lobular); for 237 women we could identify the diagnostic treatment but not the therapeutic treatment and for 15 we could not identify either therapeutic or diagnostic procedure ( Table 1 ).
The age-adjusted incidence in the LHUs with no active SP is 2.09 for malignant and 0.97/1000 for benign neoplasms (648,540 person years). In the women not yet contacted, we found the age-adjusted incidence is 2.01 for malignant and 1.14 for benign neoplasm (604,884 person years) ( Table 3 ).
In the women contacted, we found 664 malignant and 239 benign neoplasms; an age-adjusted incidence of 2.91 and 1.13, respectively (denominator: 232,806 person years). The differences among the three (no active screening, contacted and not contacted) incidence figures of benign neoplasm were not significant, while the incidence of malignant in those contacted was significantly higher than the incidence in the non-contacted populations (incidence rate ratio [IRR] 1.45 95% CI 1.32-1.60). Where diagnostic procedures (ICD-9-CM 85.1) for benign neoplasm was included, the incidence rate increased both for not-contacted and contacted women to 1.38 (95% CI 1.29-1.47) and 1.43 (95% CI 1.34-1.52), respectively, but the incidence ratio between the two populations did not change (1.04, 95% CI 0.91-1.19).
Among the contacted, the increased incidence of malignant neoplasms was entirely attributable to compliant women; in fact, the age-and SMR-adjusted incidence in this population reached 4.35/1000 (95% CI 4.19-4.51), while in the non-compliant it was 2.00/1000 (95% CI 1.88-2.10). The incidence of treated benign neoplasm was higher in the compliant population, 1.47/1000 (95% CI 1.38-1.57; 122/93,874 person years) versus 0.93/1000 in the non-compliant (95% CI 0.85-1.00; 117/138,932 person years). About one half (64/122) of the benign neoplasms treated in the compliant population occurred in women who had a negative screening diagnosis and a recommendation to re-screening, normally at two years.
The mammographic screening information system found 402 positive tests, according to our definition: the hospital information system revealed 319 malignancies, 64 benign surgical treatments and 19 had no related hospitalizations. The number of malignancies detected per 1000 screened women, the detection rate, was 6.8.
The positive predictive value, that is, the percentage of malignancies (true positives) on the total treated (all positive diagnoses), was the highest in screen detected -83% (319/ 383) -and lowest in the interval treatments -54% (67/125). The other groups have values similar to each other: 68.2% (1372/2013) in the LHUs without active programmes, 63.9% (1216/1902) in the not-yet-contacted and 70.4% (278/395) in the non-compliant women. Figure 1 shows the incidence over time after contact. The incidence of malignant interval cancer increased slowly with time; the incidence of treated benign interval neoplasms peaked just after screening. There were 22 interval malignant neoplasms in the first year after screening and 45 in the second year. Based on the incidence of malignant neoplasms in the not-yet-contacted population, the expected cases is 95 per year, the percentage of interval cancers divided by the expected number of cancer (proportional interval cancer incidence) is 23.2% (95% CI 15.1-32.9%) and 47.4% (95% CI 37.0-57.9%), respectively, for the first and the second year after the test. 16 On the other hand, the contacted population shows a statistically significant increase of about 50% in the incidence of malignant neoplasm. This increase is entirely due to compliant women, who had almost twice as many malignant neoplasms than the not-yet-contacted population.
Unnecessary treatment of benign lesions
One of the major concerns in the initial phase of the implementation of an SP is the potential for side effects and harm produced by the screening. 1 Most of the observational and experimental studies have focused on the overdiagnosis of malignant lesions without clinical relevance, some concluding that the phenomenon is a major problem, 17, 18 others that it is not. 3, 4 No study, to date, has compared the incidence rates of surgical treatment for benign neoplasms in screening programmes with those from out of screening programmes with a population-based design. The surgical treatment of benign neoplasm is indisputably considered to be unnecessary.
Generally speaking, an increase of treatments on benign neoplasms as a result of SPs is expected as a consequence of the application of a diagnostic procedure to a healthy population with low prevalence, given that no diagnostic test has 100% specificity. 19 In our study, we observed an incidence of surgically treated benign neoplasms that is about half of the incidence of malignancies in the not yet screened (1.1 and 2.0/1000 respectively), if we include diagnostic procedures for benign neoplasms, this proportion rises to about 70% (1.4/1000). The incidence of treated benign neoplasm in the notcontacted and contacted populations was the same, both excluding and including diagnostic procedures (IRR 1.0 for both). There was a statistically significant difference between incidence in the compliant and the non-compliant population. This might be due to self-selection bias: out of 122 treatments on benign neoplasm in the compliant population, 58 were interval treatments, most of which occurred immediately after the negative screening test ( Table 3 and Figure 1 ). However, this is worrisome for two reasons: the ability of screening programmes to reassure women is probably insufficient; the second concern is the reasonable suspicion that in some hospitals, protocols allow surgery for benign neoplasms.
The higher positive predictive value in the screened than in the not-screened population is unexpected because the screened population is supposed to have a lower prevalence than the not-screened population undergoing spontaneous mammography. A low positive predictive value in the notscreened groups may be the result of preventive mammograms in opportunistic screening performed on a population with very low prevalence.
The observed proportional interval cancer incidence (defined as the number of interval cancers divided by the number of expected cancers according to baseline incidence) for both the first and second year falls within 'desirable' thresholds of EU standards: 7 in the first year, we observed 23.2% and the standard is o30%, in the second year we observed 47.4% and the standard is o50%.
Methodological remarks and limits
The problems encountered during activation of the screening programmes in our region allowed us to study two populations, women contacted and not contacted for screening in the same area and during the same period, without any self-selection: in fact, the timing of contact was not related to any decision by the women or doctors, was not influenced by any physiological or clinical condition, and was based solely on logistic decisions made by the coordinating centre of the programme. We thought that it was an opportunity to compare the screening programmes with the diagnostic and therapeutic procedures performed out of screening programmes, not in an experimental setting but in the real world, which minimizes the biases of observational studies. The number of women who presented themselves spontaneously for screening is small, and we preferred to consider them in the not-contacted population to avoid any self-selection bias.
We adjusted for age and breast cancer SMR of the residence area due to imbalance between the contacted and not-contacted groups ( Table 1 ). The SMR is an ecological indicator of large areas and imbalance can occur when all women from a single municipality were contacted at the same time.
The study design produced a time shift between the notcontacted and the contacted population: in fact for the first, we only considered cancers that occurred between July 1999 and June 2001, but for the second we included also some cancers that occurred until June 2003 (because we made two years follow up after screening contact). We think that underlying secular trends of the breast neoplasm incidence, if exist, may introduce a very small bias, because the time shift between the two groups ranges from 0 to 18 months.
We considered the incident surgical treatments that did not correspond to any MSIS record as having occurred in the not-yet-contacted group. With this assumption, any error in the individual data that led to missing linkage would therefore have misclassified the case as not contacted and underestimated the ratio between contacted and not contacted. Nevertheless, the very similar incidence found in the not-screened subgroups (i.e. LHU without active organized screening programmes, incidence in the not-yetcontacted population, and the non-compliant population) supports the hypothesis that the linkage procedures did not generate any bias. In fact, the three incidence rates were calculated with different strategies.
The HIS has already been used for epidemiological studies in Lazio, and the quality of the information has been assured. 8, 9 Nevertheless, the HIS does not record the procedures occurring in clinics; consequently, some of the less invasive diagnostic procedures, like fine needle aspiration, are not included. Furthermore, some interval cases can be misclassified as screen-detected cases: if a woman has a false positive mammogram and then develops a clinically evident cancer, this is counted as a true positive mammogram; also, if a cancer develops in the contralateral breast as an interval cancer, this would also not be counted as a missed cancer but as a screen-detected cancer. The source of information for the outcome is exactly the same for the contacted and the not-contacted population and is completely independent of the screening programmes, giving the same probability to detect the treatment and the same unbiased information. In our opinion, this is unusual, and one of the benefits of our study.
Conclusions
We examined the incidence of benign and malignant neoplasm in the contacted and not-contacted populations. The results suggest that the diagnostic procedures in the contacted group do not increase the rate of unnecessary treatment of benign neoplasm, and detect 50% more malignant neoplasms. Our study supports the hypothesis that screening programmes ensure appropriate treatment.
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